Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (208)	6/1/2003 1:54:34 AM
From: Miljenko Zuanic	Read Replies (2) of 590

Tom, F*** Feurstein. He was hyping ABGX two months ago. Erik, I am not in the mood to respond where I do not agree with your view. Do you really believe that those who are at ASCO will not find out what ABX-EGF data looks? I am pissed off because PR does not imply that for their pts population data actually may be very good??? I will not comment further until I have poster reprint available. Their 2.5 mg/kg dose schedule is established. They increased 50 pts for +1 staining. It is not clear that one need high EGFr expression for drug efficacy. There are other mechanisms. Because other will have similar drug on market, they can not get NDA based on PII. They will need PIII. However, 150 pts can generate good data for nice survival benefit (with ~65%). Also, ABX-EGF is not Velcade. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next